Wong et at showed that CFS patients reach exhaustion much more rapidly than normal subjects and that they also have relatively reduced intracellular concentrations of adenosine triphosphate (ATP). They concluded that a defect of oxidative metabolism may contribute to the reduced physical endurance of CFS patients.
On the other hand, Barnes et all' did not find consistent abnormalities of glycolysis, mitochondrial metabolism or pH regulation in a group of 46 CFS patients studied with a phosphorus magnetic resonance spectroscopy. However, they showed increased acidification relative to phosphocreatine depletion and reduced acidification in a subgroup of these patients.
Several studies showed changes in mitochondrial respiration, with decreased production of intracellular ATP in patients with chronic hypophosphataemia and intracellular phosphate depletion.'01' The neuromuscular alterations resolved when serum phosphate levels returned to normal.'0 One study evaluated the effect of moderate and prolonged phosphate depletion on cellular energy production, transfer and utilisation of skeletal muscle in rats fed a phosphatedeficient diet. '3 The results of this study demonstrated that dietary phosphate restriction in the rat is associated with marked alterations in the various steps of energy metabolism. The main finding of reduced mitochondrial oxygen consumption and phosphorylation points towards an impairment in mitochondrial energy production. Possibly phosphate depletion caused a reduction in protein synthesis and consequently a reduction in the activity of many enzymes.
It is still difficult to explain in detail how phosphate depletion, even when severe, can give rise to abnormalities of muscle bioenergetics. There is little agreement on the mechanism of any of the cellular effects of abnormalities of phosphate metabolism. ' Substantial variations in serum phosphate levels have been found from one day to the next, and even during a given day, with near-normal values on some occasions.6 Serum phosphate concentration is in all probability a poor indicator of phosphate deficiency. This, together with the fact that mean laboratories set the lower limit of normal at 0.8 mmol/l, explains the mean interval of six years between symptom onset and diagnosis of PD.6 The distinctive symptoms of PD, myalgia, fatigue, and depression, are probably not directly due to the hypophosphataemia since patients with PD do not respond immediately to correction of serum phosphate. '7 Compounding all these data from the literature,9 12-16 it appears that the mechanism that leads to neuromuscular alterations in the presence of mild phosphate depletion is not yet fully understood.
One reason why CFS patients should have a decrease in oxidative metabolism is probably related to a metabolic defect that is secondary to a state of chronic underutilisation of skeletal muscle>"" If the 'deconditioning' of skeletal muscle is a clinical reality, CFS patients may be subject, in some degree, to its metabolic effect. 22 The second causal hypothesis is that an unknown trigger factor directly depresses muscle metabolism. The alterations in muscle membrane potential and in calcium transport through the sarcolemma that have been demonstrated in chronic hypophosphataemia suggests that intracellular phosphate depletion may be involved in the genesis of the symptoms.5 These alterations also induce changes in mitochondrial respiration, with decreased production of intracellular ATP,5 10 as has been previously found in CFS patients. 9 It is clear that renal re-absorption of phosphate by the proximal tubule is the main mechanism underlying phosphate homeostasis.1' Phosphate diabetes due to an abnormal renal re-absorption of phosphate can cause phosphate depletion. In our study, nine patients with CFS matched the diagnostic criteria for PD. Until now PD has not been associated with CFS, it has not been considered in differential diagnosis with CFS and the incidence of PD in patients with CFS is not known. The importance of investigating the incidence of PD in patients with CFS is related to the potential beneficial effects that could result from the treatment of PD. In fact, oral phosphate supplements and vitamin D have been shown to restore plasma phosphate concentration and muscle biochemistry to normal and to produce considerable improvement in symptoms and exercise tolerance in PD patients.18 Land et alf3 also described a patient with idiopathic renal hypophosphataemia and previously undiagnosed fatigue in whom normalisation of plasma phosphate by oral phosphate supplementation caused a marked improvement in symptoms and biochemical muscle abnormalities despite little changes in muscle phosphate concentration. The rationale of administration of phosphate supplement and vitamin D is that this combination restores phosphate homeostasis in PD patients, while in patients with hypophosphataemia, vitamin D increases active intestinal absorption of phosphate. "4 We conclude that it is of clinical significance to exclude the presence of PD, using the diagnostic criteria mentioned above, in patients with CFS. The TmPO4/GFR should be routinely determined in patients whose serum phosphate level is under 0.9 mmol/l.67 23 25 Further studies are needed to investigate the incidence of PD in patients with CFS and the effects of oral phosphate supplements and vitamin D. 
